• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

何时及如何对低危非肌肉浸润性膀胱癌进行主动监测。

When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer.

机构信息

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy.

Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy.

出版信息

Eur Urol Focus. 2023 Jul;9(4):564-566. doi: 10.1016/j.euf.2023.03.025. Epub 2023 Apr 12.

DOI:10.1016/j.euf.2023.03.025
PMID:37059619
Abstract

Active surveillance (AS) has been proposed as a possible management option for patients with recurrent low-grade non-muscle-invasive bladder cancer. Recent studies suggest that AS is a safe and effective management strategy. Nevertheless, a consensus statement is needed to standardize inclusion criteria and follow-up schedules.

摘要

主动监测 (AS) 已被提议作为复发性低级别非肌肉浸润性膀胱癌患者的一种可能的治疗选择。最近的研究表明，AS 是一种安全有效的治疗策略。然而，需要达成共识来规范纳入标准和随访计划。

相似文献

1
When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer.何时及如何对低危非肌肉浸润性膀胱癌进行主动监测。
Eur Urol Focus. 2023 Jul;9(4):564-566. doi: 10.1016/j.euf.2023.03.025. Epub 2023 Apr 12.
2
Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project.低风险非肌层浸润性膀胱癌的主动监测：意大利膀胱癌主动监测（BIAS）项目的中期结果。
BJU Int. 2016 Dec;118(6):935-939. doi: 10.1111/bju.13536. Epub 2016 Jun 13.
3
Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.低危非肌层浸润性膀胱癌主动监测失败患者的病理结局：膀胱癌意大利主动监测项目的更新和结果。
Eur Urol Oncol. 2018 Oct;1(5):437-442. doi: 10.1016/j.euo.2018.05.006. Epub 2018 Jun 5.
4
Analysing cause of death during follow-up for non-muscle-invasive bladder cancer: is there a role for watchful waiting?分析非肌层浸润性膀胱癌随访期间的死亡原因：观察等待是否起作用？
Ann R Coll Surg Engl. 2024 Jan;106(1):57-63. doi: 10.1308/rcsann.2022.0099. Epub 2022 Oct 14.
5
Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience.非肌肉浸润性膀胱癌患者主动监测失败的长期随访及相关因素：膀胱癌意大利主动监测（BIAS）经验。
Eur Urol Oncol. 2022 Apr;5(2):251-255. doi: 10.1016/j.euo.2021.05.002. Epub 2021 May 28.
6
Bladder Epicheck® for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience and follow-up proposal.用于高危非肌层浸润性膀胱癌监测的膀胱Epicheck®：初步经验及随访建议。
Actas Urol Esp (Engl Ed). 2023 Oct;47(8):471-473. doi: 10.1016/j.acuroe.2023.06.011. Epub 2023 Jun 28.
7
Active surveillance for nonmuscle invasive bladder cancer.主动监测非肌肉浸润性膀胱癌。
Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S4-S13. doi: 10.4111/icu.2016.57.S1.S4. Epub 2016 May 27.
8
Re: Management, Surveillance Patterns, and Costs Associated with Low-grade Papillary Stage Ta Non-muscle-invasive Bladder Cancer Among Older Adults, 2004-2013.关于：2004 - 2013年老年低度乳头状Ta期非肌层浸润性膀胱癌的管理、监测模式及相关成本
Eur Urol. 2023 Jan;83(1):92-93. doi: 10.1016/j.eururo.2022.10.002. Epub 2022 Oct 19.
9
Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?主动监测非肌层浸润性膀胱癌：谬误还是机遇？
Curr Opin Urol. 2022 Sep 1;32(5):567-574. doi: 10.1097/MOU.0000000000001028. Epub 2022 Jul 22.
10
Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis.主动监测非肌肉浸润性膀胱癌：系统评价和荟萃分析。
Cancer Treat Res Commun. 2021;27:100369. doi: 10.1016/j.ctarc.2021.100369. Epub 2021 Apr 3.

引用本文的文献

1
Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review.非肌层浸润性膀胱癌的主动监测：一项系统评价
Cancers (Basel). 2025 May 20;17(10):1714. doi: 10.3390/cancers17101714.
2
A Personalized, Risk-Based Approach to Active Surveillance for Prostate Cancer with Takeaways from Broader Oncology Practices: A Mixed Methods Review.一种基于风险的前列腺癌主动监测个性化方法及更广泛肿瘤学实践的经验教训：混合方法综述
J Pers Med. 2025 Feb 25;15(3):84. doi: 10.3390/jpm15030084.
3
Comment to: "Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer".
对《识别低级别中危非肌层浸润性膀胱癌主动监测的最佳候选者》的评论
World J Urol. 2025 Feb 10;43(1):113. doi: 10.1007/s00345-025-05475-x.
4
Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer.识别低级别中危非肌层浸润性膀胱癌主动监测的最佳候选者。
World J Urol. 2024 Dec 30;43(1):52. doi: 10.1007/s00345-024-05417-z.
5
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review.非肌肉浸润性膀胱癌的主动监测，生物标志物的潜在作用：系统评价。
Curr Oncol. 2024 Apr 12;31(4):2201-2220. doi: 10.3390/curroncol31040163.
6
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.吉西他滨释放膀胱内给药系统（TAR-200）在美国泌尿外科学会定义的中危非肌层浸润性膀胱癌患者中的安全性、耐受性及初步疗效：一项1b期研究
Eur Urol Open Sci. 2024 Feb 16;62:8-15. doi: 10.1016/j.euros.2024.01.013. eCollection 2024 Apr.